BeyondSpring Inc.
For the period ended Dec 31, 2025. Filed Mar 25, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 25, 2026
BYSI$0.62-1.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits, Financial Statement Schedules
| (a) | The following documents are filed as part of this Annual Report on Form 10-K: Financial Statements: See “Item 8. Financial Statements and Supplementary Data—Index to Financial Statements and Supplementary Data” herein. |
| (b) | Exhibits: The exhibits listed in the accompanying index to exhibits are filed or incorporated by reference as part of this Annual Report on Form 10-K. |
| No. | Description of Exhibit |
| 3.1(1) | Amended and Restated Memorandum and Articles of Association of BeyondSpring Inc. |
| 4.1(1) | Specimen Certificate for Ordinary Shares of BeyondSpring Inc. |
| 4.2(2) | Description of Securities Registered under Section 12 of the Exchange Act |
| 10.1(1)# | Amended and Restated Employment Agreement, dated as of November 10, 2016, between BeyondSpring U.S. and Lan Huang |
| 10.2(1)# | Form of Director and Executive Officer Indemnification Agreement |
| 10.3(1)# | BeyondSpring Inc. 2017 Omnibus Incentive Plan and related form agreements |
| 10.4(6)# | Amendment to the BeyondSpring Inc. 2017 Omnibus Incentive Plan, effective September 18, 2020 |
| 10.5(7)# | Form of Director Agreement |
| 10.6(7)# | Form of Amendment to Director Agreement |
| 10.7(8) | English Translation of the Capital Increase Agreement, dated as of June 14, 2019, among Dalian Wanchunbulin Pharmaceuticals Ltd., Wanchun Biotech Ltd. and Shenzhen Efung 9th Venture Investment Center (Limited Partnership) |
| 10.8(8) | English Translation of the Capital Increase Agreement, dated as of July 3, 2019, among Dalian Wanchunbulin Pharmaceuticals Ltd., Wanchun Biotech Ltd. and Nanjing TEEWIN Investment Partnership (Limited Partnership) |
| 10.9(5)# | Second Amendment to Employment Agreement, dated as of January 11, 2022, between BeyondSpring U.S. and Lan Huang |
| 10.10(5)# | Letter Agreement, dated as of January 13, 2022, between BeyondSpring U.S. and Lan Huang |
| 10.11(3)# | Letter Agreement, dated as of March 23, 2023, between BeyondSpring U.S. and Lan Huang |
| 10.12(4)# | Letter Agreement, dated as of October 11, 2023, between BeyondSpring U.S. and Lan Huang |
| 10.13(11)# | Letter Agreement, dated as of August 7, 2024, between BeyondSpring U.S. and Lan Huang |
| 10.14(2)# | Letter Agreement, dated as of December 20, 2025, between BeyondSpring U.S. and Lan Huang |
| 10.15(4)# | Letter Agreement, dated as of September 17, 2021, between BeyondSpring U.S. and Yingjuan (June) Lu |
| 10.16(4)# | Letter Agreement, dated as of March 20, 2024, between BeyondSpring U.S. and Yingjuan (June) Lu |
| 10.17(2)# | Letter Agreement, dated as of November 12, 2025, between BeyondSpring U.S. and Yingjuan (June) Lu |
| 10.18(9) | Purchase Agreement, dated January 24, 2025, between BeyondSpring Inc. and Winning View Investment Limited |
| 10.19(9) | Purchase Agreement, dated January 24, 2025, between BeyondSpring Inc. and FULL TECH CORPORATE DEVELOPMENT LIMITED |
| 10.20(9) | Purchase Agreement, dated January 24, 2025, between BeyondSpring Inc. and Mapfil Investment Limited |
| 10.21(10) | First Amendment to Purchase Agreement, dated February 17, 2025, between BeyondSpring Inc. and Winning View Investment Limited |
| 19.1(11) | Insider Trading Policy |
| 21.1(2) | List of Subsidiaries of BeyondSpring Inc. |
| 23.1(2) | Consent of CBIZ CPAs P.C. |
| 23.2(2) | Consent of Marcum LLP |
| 31.1(2) | Certification of Principal Executive Officer and Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| 32.1(12) | Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| 97.1(4) | Clawback Policy of BeyondSpring Inc. |
| 101.INS | XBRL Instance Document. |
| 101.SCH | XBRL Taxonomy Extension Schema Document. |
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document. |
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase Document. |
| 101.LAB | XBRL Taxonomy Extension Label Linkbase Document. |
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document. |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |
| (1) | Previously filed with the Registration Statement on Form F-1 (File No. 333-214610), as amended, initially filed on November 15, 2016, and incorporated herein by reference. |
| (3) | Incorporated by reference to the 2022 annual report on Form 20-F of BeyondSpring Inc. filed with the SEC on April 18, 2023. |
| (4) | Incorporated by reference to the 2023 annual report on Form 20-F of BeyondSpring Inc. filed with the SEC on April 29, 2024. |
| (5) | Incorporated by reference to the 2021 annual report on Form 20-F of BeyondSpring Inc. filed with the SEC on April 14, 2022. |
| (6) | Incorporated by reference to the 2020 annual report on Form 20-F of BeyondSpring Inc. filed with the SEC on April 30, 2021. |
| (7) | Previously filed with Form 6-K of BeyondSpring Inc., filed with the SEC on July 24, 2020, and incorporated by reference herein. |
| (8) | Previously filed with Form 6-K of BeyondSpring Inc., filed with the SEC on July 10, 2019, and incorporated by reference herein. |
| (9) | Previously filed with Form 8-K of BeyondSpring Inc., filed with the SEC on January 28, 2025, and incorporated by reference herein. |
| (10) | Previously filed with Form 8-K of BeyondSpring Inc., filed with the SEC on February 25, 2025, and incorporated by reference herein. |
| (11) | Incorporated by reference to the 2024 annual report on Form 10-K of BeyondSpring Inc. filed with the SEC on March 27, 2025. |
# Management contract or compensatory plan, contract, or arrangement
In reviewing the agreements included as exhibits to this Annual Report on Form 10-K, please remember they are included to provide you with information regarding their terms and are not intended to provide any other factual or disclosure information about us or the other parties to the agreements.
The agreements may contain representations and warranties by each of the parties to the applicable agreement. These representations and warranties have been made solely for the benefit of the other parties to the applicable agreement and:
| ● | should not in all instances be treated as categorical statements of fact, but rather as a way of allocating the risk to one of the parties if those statements prove to be inaccurate; |
| ● | have been qualified by disclosures that were made to the other party in connection with the negotiation of the applicable agreement, which disclosures are not necessarily reflected in the agreement; |
| ● | may apply standards of materiality in a way that is different from what may be viewed as material to you or other investors; and |
| ● | were made only as of the date of the applicable agreement or such other date or dates as may be specified in the agreement and are subject to more recent developments. |
Accordingly, these representations and warranties may not describe the actual state of affairs as of the date they were made or at any other time.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.